Combining Daratumumab with VRd Improves Outcomes in Patients with Transplant-Ineligible or Transplant-Deferred Newly Diagnosed Multiple Myeloma By Ogkologos - March 3, 2025 547 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CEPHEUS study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Reflections from the World Cancer Congress November 30, 2022 FDA Grants Accelerated Approval to Sunvozertinib for Metastatic Non-Small Cell Lung... July 25, 2025 Finding Hope During Cancer and Pregnancy: “Your Stories” Podcast December 2, 2020 Adding PD1 Inhibitor to Neoadjuvant Chemotherapy Significantly Increases the pCR Rate... February 12, 2025 Load more HOT NEWS More Evidence that Ruxolitinib Benefits Some Patients with Graft-Versus-Host Disease Closing the gap: How new screening interventions could reduce inequalities in... Topotecan–Berzosertib Combination Shows Promise against Small Cell Lung Cancer Potential of Molecular Profiling to Refine Surgical and Radiotherapy Decision-Making in...
